Template for reporting results of HER2 (ERBB2) biomarker testing of specimens from patients with adenocarcinoma of the stomach or esophagogastric junction

Archives of Pathology and Laboratory Medicine

Volumn 139, Issue 5, 2015, Pages 618-620

  Bartley, Angela N ^a   Christ, Jessi ^b   Fitzgibbons, Patrick L ^c   Hamilton, Stanley R ^d   Kakar, Sanjay ^e,f   Shah, Manish A ^g   Tang, Laura H ^h   Troxell, Megan L ⁱ  

^a ST JOSEPH MERCY HOSPITAL   (United States)

^b Cancer Registry Sanford Health Medical Center   (United States)

^c ST JUDE MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; CHECKLIST; DOCUMENTATION; GENETICS; HUMAN; LOWER ESOPHAGUS SPHINCTER; MEDICAL SOCIETY; METABOLISM; METHODOLOGY; PATHOLOGY; PROCEDURES; STANDARDS; STOMACH; STOMACH TUMOR; UNITED STATES;

ADENOCARCINOMA; CHECKLIST; DOCUMENTATION; ESOPHAGOGASTRIC JUNCTION; HUMANS; RECEPTOR, ERBB-2; RESEARCH DESIGN; SOCIETIES, MEDICAL; STOMACH; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84928966391     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2014-0395-CP     Document Type: Article

References (11)

1. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986;232(4758):1644-1646.
2. Ménard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003;22(42):6570-6578.
3. Liu L, Wu N, Li J. Novel targeted agents for gastric cancer. J Hematol Oncol. 2012;5:31.
4. Boku N. HER2 positive gastric cancer. Gastric Cancer. 2014;17(1):1-12.
5. Ajani JA, Bentrem DJ, Besh S, et al. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013;11(5):531-546.
6. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010;376(9742):687-697.
7. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797-805.
8. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol. 2011;18(1):53-59.
9. Bang YJ. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. J Clin Gastroenterol. 2012;46(8):637-648.
10. Pirrelli M, Caruso ML, Di Maggio M, Armentano R, Valentini AM. Are biopsy specimens predictive of HER2 status in gastric cancer patients? Dig Dis Sci. 2013;58(2):397-404.
11. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241-256.